Higher Maternal BMI in Early Pregnancy Tracks with Greater Offspring MS Risk
A nationwide Swedish cohort has linked maternal body mass index in early pregnancy with a higher rate of multiple sclerosis in offspring, adding a prenatal signal to a disease that is usually discussed through genetics, postnatal immune triggers, and adolescence-to-adulthood environmental exposures. The finding is especially striking because BMI was captured prospectively at the first antenatal visit, well before offspring neurologic disease could have influenced maternal health behaviors or clinical recording.
The cohort was large enough to make the pattern hard to dismiss as a statistical accident. Investigators followed 1,524,863 singleton children born in Sweden from 1992 through 2007 using national health and demographic registers, then tracked them through 2025. During follow-up, 1539 offspring developed MS, with a median diagnosis age of 24 years. Even in a disorder as uncommon as MS, that scale gives the analysis unusual weight.
The overall incidence remained low across exposure groups, but the gradient was consistent. MS incidence rates were 0.37 per 10,000 person-years among offspring of underweight women and the same rate among offspring of normal-weight women, rising to 0.42 per 10,000 person-years in the overweight group and 0.45 per 10,000 person-years in the obesity group. The absolute difference is small, yet the relative pattern persisted after adjustment for measured confounders, which is exactly the kind of result that pushes attention toward biology rather than chance alone.
Compared with normal-weight women, early-pregnancy overweight was associated with an adjusted hazard ratio of 1.20, with a 95% confidence interval of 1.05 to 1.37. Obesity carried an adjusted hazard ratio of 1.35, with a 95% confidence interval of 1.11 to 1.64. A dose-response pattern also emerged when BMI was modeled continuously: each 1-unit increase in maternal BMI corresponded to a 3% higher hazard of overall offspring MS, and the same incremental rise was associated with a 4% higher hazard of pediatric-onset MS and a 3% higher hazard of adult-onset MS.
Why the Prenatal Metabolic Milieu Matters
The most biologically plausible interpretation is that maternal adiposity marks a gestational environment shaped by chronic low-grade inflammation, altered lipid metabolism, insulin resistance, and endocrine changes that may influence fetal immune programming. MS does not arise in a vacuum. It reflects an immune system that later turns against central nervous system myelin, and early-life immune development is exquisitely sensitive to maternal metabolic signals. If the fetal immune set point is being nudged in utero, the effect may remain silent for years before it appears as neurologic disease in young adulthood.
The exposure window matters. BMI was measured at the first antenatal visit, which anchors the analysis to early pregnancy rather than late gestation complications. That design reduces the chance that the association is simply a surrogate for preeclampsia, preterm birth, or other adverse pregnancy outcomes that can cluster with obesity. In fact, the excess risk persisted after excluding pregnancies with major complications, which argues that the signal is not fully explained by pregnancy morbidity alone.
This is an important epidemiologic distinction. The concern is not that maternal obesity directly “causes” MS in a simple linear way. The more credible interpretation is that maternal adiposity may help shape immune maturation, inflammatory tone, and perhaps the fetal epigenetic environment during a critical developmental window. For a disease with a long latency period, a prenatal influence is entirely plausible even if the clinical consequences do not become visible until adolescence or adulthood.
Adult-Onset and Pediatric-Onset MS Followed the Same Direction
Onset-specific analyses pointed in the same direction for both adult-onset and pediatric-onset MS, although the pediatric estimates were less precise. Adult-onset disease carried the clearest signal, which fits the reality that most MS diagnoses in the cohort occurred in early adulthood rather than childhood. The pediatric analyses should not be overread, but they do make the association harder to chalk up to a single age-specific pathway.
One sentence captures the central result: higher maternal BMI was followed by higher offspring MS risk. Another captures the clinical caution: the effect size was modest, not dramatic, and the absolute risk remained low.
The study therefore does not support panic or a new screening pathway for children of women with overweight or obesity. It does, however, strengthen the case that maternal metabolic health belongs in the etiologic conversation about MS, alongside vitamin D, smoking, infection history, and genetic susceptibility. Registry data of this scale rarely point to a single mechanism, but they can reveal where the biology is worth interrogating more closely.
What the Registry Design Can and Cannot Prove
The analysis draws strength from its population base, prospective exposure capture, and long follow-up. The MS definition was also conservative: offspring needed at least three ICD-10 G35 codes recorded on separate dates, which improves specificity compared with a single diagnostic claim. That kind of case definition matters in a low-prevalence neurologic disorder where diagnostic miscoding can otherwise blur the signal.
Still, registry studies are not mechanistic experiments. BMI is an imperfect proxy for adiposity and metabolic state, and it cannot separate fat distribution, diet quality, inflammatory burden, or insulin resistance. Residual confounding remains possible, especially from family-level factors that are difficult to measure completely in administrative data. Paternal BMI, shared environment, maternal smoking patterns, and other early-life exposures may all overlap with maternal weight in ways that are not fully captured by routine registers.
Even with those limits, the consistency across categorical and continuous analyses gives the findings practical epidemiologic force. The pattern was not confined to one extreme BMI group, and it did not disappear when major pregnancy complications were removed from the cohort. In a field where prenatal origins of chronic neurologic disease are still being mapped, that is a meaningful result.
The study was approved by the Swedish Ethical Review Authority, and informed consent was waived because only anonymized registry data were used. Data availability remains restricted by privacy and data protection rules, so external replication will depend on other national cohorts with similar linkage capacity.
What remains now is a mechanistic question, not a statistical one: which components of the maternal metabolic environment are most relevant to offspring immune programming, and at what point in gestation do they exert the greatest influence? The answer will determine whether this association stays an epidemiologic signal or becomes a target for prevention research.